首页> 外文期刊>Cancer gene therapy >Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA
【24h】

Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA

机译:E6 siRNA诱导人乳头瘤病毒18阳性子宫颈癌细胞死亡

获取原文
获取外文期刊封面目录资料

摘要

Human cervical cancer is caused by high-risk types of human papillomavirus (HPV) such as HPV16 and HPV18, which possess the E6 and E7 oncogenes, whose concurrent expression is a prerequisite for cancer development and maintaining malignant phenotypes. Silencing these oncogenes is considered to be applicable in molecular therapies of human cervical cancer. However, it remains to be determined whether E6, E7, or both should be silenced to obtain most efficient antitumor activity by an HPV small-interfering RNA (siRNA). Herein, we report two types of siRNAs targeting HPV18 E6, that exerted a negative growth effect on HPV18-positive cervical cancer cells (HeLa and SW756), in part, inducing cell death. One siRNA (Ex-18E6), designed to target both E6-E7 mRNA and its splicing variant, E6*I-E7 mRNA, efficiently knocked down both E6 and E7 expression. The other (Sp-18E6), designed to specifically target E6-E7 mRNA but not E6*I-E7 mRNA, suppressed E6 to a similar level as Ex-18E6; however, it less efficiently inhibited E7 as compared to Ex-18E6. Although both siRNAs induced cell death, Sp-18E6 siRNA induced more prominent cell death than Ex-18E6. Our results suggest that E6-specific suppression may induce more potent anticancer activity than simultaneous E6 and E7 suppression, and that E6-specific targeting is a promising strategy for siRNA-based therapy for HPV-positive cervical cancer.
机译:人宫颈癌是由高危类型的人乳头瘤病毒(HPV)引起的,例如HPV16和HPV18,它们具有E6和E7癌基因,它们的同时表达是癌症发展和维持恶性表型的前提。沉默这些癌基因被认为可用于人类宫颈癌的分子疗法。但是,是否应通过HPV小干扰RNA(siRNA)沉默E6,E7或两者是否沉默以获得最有效的抗肿瘤活性仍有待确定。本文中,我们报道了两种靶向HPV18 E6的siRNA,它们对HPV18阳性子宫颈癌细胞(HeLa和SW756)产生负增长作用,部分是诱导细胞死亡。一种针对E6-E7 mRNA及其剪接变体E6 * I-E7 mRNA的siRNA(Ex-18E6)有效地敲低了E6和E7的表达。另一个(Sp-18E6)被设计为专门针对E6-E7 mRNA,但不是E6 * I-E7 mRNA,将E6抑制到与Ex-18E6类似的水平。但是,与Ex-18E6相比,它抑制E7的效率较低。尽管两种siRNA均可诱导细胞死亡,但Sp-18E6 siRNA较Ex-18E6诱导更明显的细胞死亡。我们的结果表明,与同时抑制E6和E7相比,对E6的特异性抑制可能诱导更强的抗癌活性,并且对E6的特异性靶向是基于siRNA的HPV阳性宫颈癌治疗的有希望的策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号